Latest News


13 Feb

FDA Approves First Generic Version of Advair

Asthma and COPD patients who use the Advair Diskus got some good news last week when the FDA approved the first generic version of the respiratory medication. Generic Advair Diskus is indicated for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in… Read more »

Read More
16 Jan

Avoiding Drug-Drug Interaction for Patients

When delivering quality patient care, safety remains supreme. Taking the time to be mindful of your patient’s history and background will help you avoid harmful drug-drug interaction for patients. AARC Member Doug Gardenhire, EdD, RRT, RRT-NPS, FAARC, shares his tips on how RTs can avoid drug-drug interaction. “Drug safety is very important in respiratory therapy… Read more »

Read More
09 Nov

FDA Announces New OTC Option, AARC Raises Concerns

On Thursday, Nov. 8, the Food and Drug Administration (FDA) announced approval of Primatene Mist for over-the-counter (OTC) use to provide temporary relief for symptoms of mild, intermittent asthma for patients age 12 years and older who have been diagnosed with asthma by a health care provider. The American Association for Respiratory Care came out… Read more »

Read More
11 Jul

USP 800: What RTs Need to Know

USP Chapter 800 takes effect July 1, 2018, and medical facilities are likely reviewing and implementing all of the precautions set forth in the chapter now in order to meet the new standards. Health care professionals who administer hazardous drugs (HDs) will come under new protections as of July 1, 2018. USP Chapter 800 will… Read more »

Read More